|
|
| | LOXIGLUMIDE Basic information |
| Product Name: | LOXIGLUMIDE | | Synonyms: | 4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid;4-[(3,4-dichlorophenyl)carbonylamino]-5-[3-methoxypropyl(pentyl)amino]-5-oxo-pentanoic acid;5-[amyl(3-methoxypropyl)amino]-4-[(3,4-dichlorobenzoyl)amino]-5-keto-valeric acid;LoxigluMide (CR1505);LOXIGLUMIDE;(+-)-4-((3,4-dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxope;(+-)--5-oxo;anoicacid | | CAS: | 107097-80-3 | | MF: | C21H30Cl2N2O5 | | MW: | 461.38 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 107097-80-3.mol |  |
| | LOXIGLUMIDE Chemical Properties |
| Melting point | 113-115℃ | | Boiling point | 632.2±55.0 °C(Predicted) | | density | 1.233±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ≥5mg/mL | | pka | pKa ~5(at 25℃) | | form | powder | | color | white to beige | | CAS DataBase Reference | 107097-80-3 |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | LOXIGLUMIDE Usage And Synthesis |
| Uses | Loxiglumide is a CCK1 antagonist. Suppresses CCK-induced proliferation of acinar cells. Inhibits pancreatic secretion of digestive enzymes. Active in vivo. | | Definition | ChEBI: Loxiglumide is an organic molecular entity. | | Biochem/physiol Actions | Loxiglumide is a small-molecule antagonist of the cholecystokinin receptor CCKA. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying. | | Safety Profile | A poison by
intravenous. Moderately toxic by ingestion,
intraperitoneal, and subcutaneous routes.
When heated to decomposition it emits
toxic vapors of NOx and Cl-. | | storage | Store at -20°C |
| | LOXIGLUMIDE Preparation Products And Raw materials |
|